Publications by authors named "Kenneth Wha Eng"
Colorectal carcinoma (CRC) is a heterogeneous group of tumors with varying therapeutic response and prognosis, and evidence suggests the tumor immune microenvironment (TIME) plays a pivotal role. Using advanced molecular and spatial biology technologies, we aimed to evaluate the TIME in patients with CRC to determine whether specific alterations in the immune composition correlated with prognosis. We identified primary and metastatic tumor samples from 31 consented patients, which were profiled with whole-exome sequencing and bulk RNA-seq.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are investigating the molecular differences between primary and metastatic upper tract urothelial carcinoma (UTUC) using advanced sequencing and imaging techniques on tumor samples from patients.
- Their findings reveal that genomic alterations in tumors can differ significantly between the primary and metastatic sites, while the overall molecular and immune characteristics remain stable.
- This study highlights the importance of single-cell analysis in understanding cancer evolution and suggests that different treatment strategies may be needed for primary and metastatic UTUC due to these genomic discrepancies.
Purpose: Patients with neuroendocrine prostate cancer (NEPC) are often managed with immunotherapy regimens extrapolated from small-cell lung cancer (SCLC). We sought to evaluate the tumor immune landscape of NEPC compared with other prostate cancer types and SCLC.
Experimental Design: In this retrospective study, a cohort of 170 patients with 230 RNA-sequencing and 104 matched whole-exome sequencing data were analyzed.
Unlabelled: The rarity of malignant Hodgkin and Reed Sternberg (HRS) cells in classic Hodgkin lymphoma (cHL) limits the ability to study the genomics of cHL. To circumvent this, our group has previously optimized fluorescence-activated cell sorting to purify HRS cells. Using this approach, we now report the whole-genome sequencing landscape of HRS cells and reconstruct the chronology and likely etiology of pathogenic events leading to cHL.
View Article and Find Full Text PDFGenetic alterations in RET lead to activation of ERK and AKT signaling and are associated with hereditary and sporadic thyroid cancer and lung cancer. Highly selective RET inhibitors have recently entered clinical use after demonstrating efficacy in treating patients with diverse tumor types harboring RET gene rearrangements or activating mutations. In order to understand resistance mechanisms arising after treatment with RET inhibitors, we performed a comprehensive molecular and genomic analysis of a patient with RET-rearranged thyroid cancer.
View Article and Find Full Text PDFLow-grade, low-stage endometrioid carcinomas (LGLS EC) demonstrate 5-yr survival rates up to 95%. However, a small subset of these tumors recur, and little is known about prognostic markers or established mutation profiles associated with recurrence. The goal of the current study was to identify the molecular profiles of the primary carcinomas and the genomic differences between primary tumors and subsequent recurrences.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the effectiveness of on-site plasma-based next-generation sequencing (NGS) for analyzing circulating tumor DNA (ctDNA) in cancer patients, particularly those with metastatic disease.
- Results show that the NGS test has a higher success rate in detecting genetic alterations from plasma samples compared to primary tumor samples, demonstrating its potential utility in clinical practice.
- The findings support the integration of plasma tests into routine oncology management, as they provide valuable information to guide precision therapy while reducing the need for invasive tissue biopsies.
Purpose: Molecular profiling of cancer is increasingly common as part of routine care in oncology, and germline and somatic profiling may provide insights and actionable targets for men with metastatic prostate cancer. However, all reported cases are of deidentified individuals without full medical and genomic data available in the public domain.
Patient And Methods: We present a case of whole-genome tumor and germline sequencing in a patient with advanced prostate cancer, who has agreed to make his genomic and clinical data publicly available.
Article Synopsis
- The study explores the effectiveness of combining anchored multiplex PCR (AMP)-based next-generation sequencing (NGS) with whole-exome sequencing (WES) to uncover additional drug targets in solid tumors.
- AMP-based NGS identified 48 gene fusions in over half of the samples tested, with a significant portion deemed actionable, enhancing the overall drug target detection when combined with WES results.
- The research underscores the utility of an integrated genomic approach, showing that using multiple NGS methods can improve the identification of actionable mutations in cancer, even from older tissue samples.
Genetic profiling of resected tumor or biopsy samples is increasingly used for cancer diagnosis and therapy selection for thyroid and other cancer types. Although mutations occur in cell DNA and are typically detected using DNA sequencing, recent attempts focused on detecting pathogenic variants from RNA. The aim of this study was to determine the completeness of capturing mutations using RNA sequencing (RNA-Seq) in thyroid tissue and fine-needle aspiration (FNA) samples.
View Article and Find Full Text PDF